At a Glance
- First-in-class MYC condensate modulator selected as development candidate for oncology.
- Targets “undruggable” MYC transcription factor via biomolecular condensate disruption.
- Preclinical data show potent MYC inhibition, favorable PK, and tumor regression in models.
- IND-enabling studies to address MYC-driven cancers.
Written By: Nikita Chaudhari BPharm
Reviewed By: Pharmacally Editorial Team
Dewpoint Therapeutics, a biotech pioneer in condensate biology, has advanced its oncology pipeline by nominating a first-in-class MYC condensate modulator as a development candidate (DC).
The small-molecule candidate targets the transcription factor MYC, a notorious “undruggable” driver of cancer proliferation that’s dysregulated in numerous tumor types. Unlike traditional approaches seeking direct binding sites, Dewpoint’s strategy disrupts MYC’s function by modulating biomolecular condensates dynamic, membraneless cellular compartments that organize its transcriptional activity.
What Are Biomolecular Condensates?
Condensates are membraneless organelles that form dynamically throughout the cell via phase separation. These subcellular compartments organize and concentrate molecules, enabling diverse biochemical processes. Dysregulation of condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary, and neurological disorders. Condensate-modulating drugs (c-mods) provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more at condensates.com.
Preclinical studies showed the DC potently and selectively inhibits MYC-driven transcription, with strong pharmacokinetic properties and tumor regression in MYC-dependent models. These results pave the way for IND-enabling studies.
“MYC has long been one of the most compelling and most elusive targets in oncology,” said Dr. Isaac Klein, MD, PhD, Dewpoint’s Chief Scientific Officer. “Advancing a MYC development candidate underscores the power of Dewpoint’s condensate-modulating platform to tackle foundational drivers of disease that have resisted conventional drug discovery approaches.”
Dewpoint’s c-mods represent a novel modality, leveraging phase separation for greater selectivity and fewer off-target effects. The company integrates AI-driven discovery with its pipeline targeting tough oncology and neurological diseases.
This milestone bolsters hopes that condensate biology could unlock therapies for MYC-addicted cancers, reshaping how biotech tackles complex molecular targets.
References
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate, 11 February 2026, Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate | Dewpoint Therapeutics